Fig. 4From: Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patientsThe cost-effectiveness acceptability curves showing the chance of obtaining net benefits with the NGS compared to standard strategies, at different hypothetical willingness-to-pay thresholdsBack to article page